NCT06655870 is a Phase 1 clinical trial of mRNA-0184 in Healthy Participants, sponsored by ModernaTX, Inc..

Who is sponsoring NCT06655870?

NCT06655870 is sponsored by ModernaTX, Inc..

What drugs are being tested in NCT06655870?

Interventions in NCT06655870: mRNA-0184.

What condition does NCT06655870 study?

NCT06655870 studies Healthy Participants.

Is NCT06655870 still recruiting?

NCT06655870 is currently active, enrolled. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT06655870

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

Active, enrolled Phase 1 Last updated 20 January 2026

What this trial tests

Phase 1 trial testing mRNA-0184 in Healthy Participants in 52 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 October 2024

Primary endpoint
23 June 2026

23 June 2026

Quick facts

Lead sponsor	ModernaTX, Inc.
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	52
Start date	31 October 2024
Primary completion	23 June 2026
Estimated completion	23 June 2026
Sites	1 location across Australia

Drugs / interventions tested

mRNA-0184 — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

ModernaTX, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the safety of mRNA-0184 in healthy participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Therapeutic mRNA vaccine applications in oncology.
Elliott L, Foster T, Castillo P, Mendez-Gomez H, et al · · 2025 · cited 4× · PMID 40336197 · DOI 10.1016/j.ymthe.2025.04.044

Verify or expand the search:

Other trials of mRNA-0184

Trials testing the same drug.

NCT06243770 — Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Pa · Phase 1 · completed
NCT05659264 — A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure · Phase 1 · completed

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other ModernaTX, Inc. trials

Trials by the same sponsor.

NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06655870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06655870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing